Thalidomide-NH-PEG1-NH2 hydrochloride

Background Introduction

Thalidomide-NH-PEG1-NH2 hydrochloride is a versatile E3 ligase ligand-linker conjugate widely employed in the field of targeted protein degradation, particularly in PROTAC technology. It combines a thalidomide-based moiety, which binds to the cereblon (CRBN) E3 ubiquitin ligase, with a short, hydrophilic PEG1 linker and terminal amine functionality. This structure enables researchers and medicinal chemists to construct custom PROTAC molecules for probing and drug discovery applications.

Mechanism

Thalidomide-NH-PEG1-NH2 hydrochloride operates by exploiting the ubiquitin-proteasome system. The thalidomide portion selectively binds to the CRBN E3 ligase, one of the key components in the E3 ubiquitin ligase complex. The PEG1 linker provides hydrophilicity and optimal spatial arrangement, while the terminal amine allows for easy conjugation with various ligands targeting proteins of interest. When incorporated into a PROTAC, this conjugate brings the E3 ligase and target protein into proximity, leading to ubiquitination and subsequent proteasomal degradation of the target protein.

Applications

This product is ideal for the efficient design and synthesis of PROTACs and molecular glues. Thalidomide-NH-PEG1-NH2 hydrochloride is widely used in early-stage drug development, target validation, and functional genomics studies. Researchers utilize it to create customized PROTACs that induce selective degradation of disease-relevant proteins, facilitating novel therapeutic approaches for oncology, immunology, neurodegenerative diseases, and beyond. Its high purity and robust performance make it a preferred building block for academic and pharmaceutical research in targeted protein degradation.

Thalidomide-NH-PEG1-NH2 hydrochloride serves as a versatile E3 Ligase Ligand-Linker Conjugate in the development of PROTACs, facilitating targeted protein degradation by enhancing selectivity and efficacy. The following provides a detailed description of this molecule's linker, ligand, and selection of target protein ligands.

Linker: This molecule features a PEG1 linker, characterized by its short length and flexible nature, which provides optimal spatial arrangement between the ligand and target protein. The linker is non-cleavable, ensuring stability during the degradation process.

Ligand: The ligand component is based on Thalidomide, a well-characterized E3 ligase recruiter known for its ability to bind to the cereblon (CRBN) protein. Its structural configuration promotes efficient recruitment of the ubiquitin-proteasome system for targeted protein degradation.

Reactive Site: The molecule contains a terminal amine group (-NH2) that serves as the reactive site for coupling with the target protein ligand. Recommended reaction types include amide bond formation or reductive amination for robust covalent attachment.

Recommended Target Protein Ligand: Compatible warheads for this molecule include electrophilic groups such as acrylamides or chloroacetamides, which facilitate covalent bonding with cysteine residues on the target protein. These warheads offer the advantage of forming stable, irreversible interactions, enhancing the specificity and potency of the resulting PROTACs in experimental studies.